NEW YORK, April 30, 2015 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the District of New Jersey on behalf of those who purchased shares of Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company") (NasdaqGM: AERI), during the period between August 6, 2014 and April 23, 2015 inclusive (the "Class Period").
The complaint alleges that during the Class Period, defendants made false and misleading statements and/or failed to disclose adverse information regarding the Company's prospects for Rhopressa, including that Rhopressa was not performing as well as timolol and would not lead to commercial success for Aerie.
On April 23, 2015, Aerie Pharmaceuticals reported its Phase 3 trial evaluating its lead product candidate, "Rhopressa™, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily Rhopressa™ compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma."
Following this news, shares of Aerie fell $22.52 or 63.63%, to close at $12.87 on April 24, 2015.
Plaintiff seeks to recover damages on behalf of all shareholders who purchased shares of Aerie during the Class Period described above.
No Class has yet been certified in the above action. If you wish to review a copy of the Complaint, to discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Aerie you have until June 29, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC